COLLEGE STATION - The U.S. Department of Health and Human Services has approved Texas A&M University System and GlaxoSmithKline Plc’s plans to build a $91 million facility to manufacture influenza vaccines.
The 110,000-sf manufacturing center will serve as the anchor of Texas A&M's Center for Innovation in Advanced Development and Manufacturing.
The facility is projected to add more than 6,800 direct and related jobs to the state. In addition, it is expected to bring in more than $41 billion in expenditures to the state of Texas over the next 25 years.
Once built and operational, the center’s influenza manufacturing facility will be able to supply 50 million doses of pandemic influenza vaccine within four months of an outbreak. The project will break ground in summer 2013.
Our twice-weekly e-newsletter provides a quick overview of Texas real estate markets. Because your time is valuable.